Related references
Note: Only part of the references are listed.MSINGB: A Novel Computational Method Based on NGBoost for Identifying Microsatellite Instability Status from Tumor Mutation Annotation Data
Jinxiang Chen et al.
INTERDISCIPLINARY SCIENCES-COMPUTATIONAL LIFE SCIENCES (2023)
Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy
Hanju Hua et al.
Frontiers in Immunology (2023)
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Cervantes et al.
ANNALS OF ONCOLOGY (2023)
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The Application of Metabolomics in Recent Colorectal Cancer Studies: A State-of-the-Art Review
Andrew Gold et al.
CANCERS (2022)
Digestive cancer incidence and mortality among young adults worldwide in 2020: A population-based study
Jian Li
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2022)
Development and validation of a radiomics-based nomogram for the preoperative prediction of microsatellite instability in colorectal cancer
Mingliang Ying et al.
BMC CANCER (2022)
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy
Keigo Chida et al.
CLINICAL CANCER RESEARCH (2022)
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial
Federica Morano et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Giovanni Crisafulli et al.
CANCER DISCOVERY (2022)
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
Beom Kyung Kim et al.
CANCERS (2022)
Microsatellite Instability and Metastatic Colorectal Cancer - A Clinical Perspective
Tomas Buchler
FRONTIERS IN ONCOLOGY (2022)
A single center phase 2 study of anti-PD-1 antibody plus bevacizumab and FOLFIRI as second-line treatment for patients with MSI-H metastatic colorectal cancer.
Hongli Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Exploring immunotherapy in colorectal cancer
Junyong Weng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas
Minsun Jung et al.
MODERN PATHOLOGY (2022)
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Andrea Cercek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Tumor Antigenicity and a Pre-Existing Adaptive Immune Response in Advanced BRAF Mutant Colorectal Cancers
Elena Bolzacchini et al.
CANCERS (2022)
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dong-Rui Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Polyamines in cancer: integrating organismal metabolism and antitumour immunity
Cassandra E. Holbert et al.
NATURE REVIEWS CANCER (2022)
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
Anwaar Saeed et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer
Chung-Ta Lee et al.
PATHOLOGY RESEARCH AND PRACTICE (2021)
Targeted next-generation sequencing-based detection of microsatellite instability in colorectal carcinomas
Yunbeom Lee et al.
PLOS ONE (2021)
Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair
Toky Ratovomanana et al.
GASTROENTEROLOGY (2021)
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity
Andrew Chow et al.
CANCER CELL (2021)
Spatially organized multicellular immune hubs in human colorectal cancer
Karin Pelka et al.
CELL (2021)
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
Antoine Hollebecque et al.
CLINICAL CANCER RESEARCH (2021)
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
Francesca Corti et al.
EUROPEAN JOURNAL OF CANCER (2021)
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)-NRG-GI004/SWOG-S1610.
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Dennis Doleschel et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Filippo Pietrantonio et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer
Shuyi Cen et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
Yaohui Gao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Multi-center real-world comparison of the fully automated Idylla™ microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer
Ana Velasco et al.
VIRCHOWS ARCHIV (2021)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Microsatellite instability: a review of what the oncologist should know
Kai Li et al.
CANCER CELL INTERNATIONAL (2020)
Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer
Zuzana Snahnicanova et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2020)
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
Emilie Picard et al.
FRONTIERS IN IMMUNOLOGY (2020)
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study
Eric X. Chen et al.
JAMA ONCOLOGY (2020)
Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer
Hae-Ock Lee et al.
NATURE GENETICS (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Metabolomic Markers of Colorectal Tumor With Different Clinicopathological Features
Zhiping Long et al.
FRONTIERS IN ONCOLOGY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The impact of ARID1A mutation on molecular characteristics in colorectal cancer
Ryuma Tokunaga et al.
EUROPEAN JOURNAL OF CANCER (2020)
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
David Lau et al.
ESMO OPEN (2020)
Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1
Mara Roxana Rubinstein et al.
EMBO REPORTS (2019)
Immunotherapy in colorectal cancer: rationale, challenges and potential
Karuna Ganesh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato et al.
PLOS ONE (2019)
Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1
Chamutal Gur et al.
ONCOIMMUNOLOGY (2019)
Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors
Nicolas J. Llosa et al.
CLINICAL CANCER RESEARCH (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
Frank A. Sinicrope et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Analysis of the transcriptomic features of microsatellite instability subtype colon cancer
Haiwei Wang et al.
BMC CANCER (2019)
Evaluation of a Fully Automated Idylla Test System for Microsatellite Instability in Colorectal Cancer
Xiang Li et al.
CLINICAL COLORECTAL CANCER (2019)
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Noah Federman et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2019)
The mutational footprints of cancer therapies
Oriol Pich et al.
NATURE GENETICS (2019)
Adaptive mutability of colorectal cancers in response to targeted therapies
Mariangela Russo et al.
SCIENCE (2019)
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions
Emiliano Cocco et al.
CANCER RESEARCH (2019)
Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation
Aoife J. McCarthy et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2019)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer
Jonas Janikovits et al.
ONCOIMMUNOLOGY (2018)
TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection
Ting Chen et al.
HUMAN PATHOLOGY (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
The gut microbiota influences anticancer immunosurveillance and general health
Bertrand Routy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Catherine S. Grasso et al.
CANCER DISCOVERY (2018)
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas
Tsuyoshi Hamada et al.
ONCOIMMUNOLOGY (2018)
Complex pattern of immune evasion in MSI colorectal cancer
Mine Ozcan et al.
ONCOIMMUNOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
Ankur Chakravarthy et al.
NATURE COMMUNICATIONS (2018)
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A. Fabrizio et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability
Eun Ji Choi et al.
PATHOLOGY & ONCOLOGY RESEARCH (2017)
Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS
Esko A. Kautto et al.
ONCOTARGET (2017)
Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21
Yongzhi Yang et al.
GASTROENTEROLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil et al.
PLOS ONE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
A molecular portrait of microsatellite instability across multiple cancers
Isidro Cortes-Ciriano et al.
NATURE COMMUNICATIONS (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
Anita Sveen et al.
GENOME MEDICINE (2017)
Comprehensive Analysis of Hypermutation in Human Cancer
Brittany B. Campbell et al.
CELL (2017)
Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
Kosuke Mima et al.
GUT (2016)
MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas
Lama Farchoukh et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics
Farshad Farshidfar et al.
BRITISH JOURNAL OF CANCER (2016)
Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Etienne Becht et al.
CLINICAL CANCER RESEARCH (2016)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik et al.
IMMUNITY (2016)
Classification and characterization of microsatellite instability across 18 cancer types
Ronald J. Hanse et al.
NATURE MEDICINE (2016)
Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer
Ellen Stelloo et al.
ONCOTARGET (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Marios Giannakis et al.
CELL REPORTS (2016)
Partial recovery of microbiomes after antibiotic treatment
Frederic Raymond et al.
GUT MICROBES (2016)
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Etienne Becht et al.
GENOME BIOLOGY (2016)
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy
Pauline Maby et al.
CANCER RESEARCH (2015)
Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
Chamutal Gur et al.
IMMUNITY (2015)
Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway
Miki Ito et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Mismatch Repair
Richard Fishel
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
Mihaela Angelova et al.
GENOME BIOLOGY (2015)
An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy
Neeraj Lal et al.
ONCOIMMUNOLOGY (2015)
Prevalence of Somatic MutL Homolog 1 Promoter Hypermethylation in Lynch Syndrome Colorectal Cancer
Leticia Moreira et al.
CANCER (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
Beifang Niu et al.
BIOINFORMATICS (2014)
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch et al.
CLINICAL CANCER RESEARCH (2014)
Microsatellite Instability Detection by Next Generation Sequencing
Stephen J. Salipante et al.
CLINICAL CHEMISTRY (2014)
Heterogenous mismatch-repair status in colorectal cancer
Patrick Joost et al.
DIAGNOSTIC PATHOLOGY (2014)
The BRAF Oncoprotein Functions through the Transcriptional Repressor MAFG to Mediate the CpG Island Methylator Phenotype
Minggang Fang et al.
MOLECULAR CELL (2014)
Multiple Sporadic Colorectal Cancers Display a Unique Methylation Phenotype
Victoria Gonzalo et al.
PLOS ONE (2014)
Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks
Hui Zhao et al.
ELIFE (2014)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2013)
Identification of Candidate Oncogenes in Human Colorectal Cancers With Microsatellite Instability
Alexandra E. Gylfe et al.
GASTROENTEROLOGY (2013)
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Gabriela Bindea et al.
IMMUNITY (2013)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Challenging cases encountered in colorectal cancer screening for Lynch syndrome reveal novel findings: nucleolar MSH6 staining and impact of prior chemoradiation therapy
Oana M. Radu et al.
HUMAN PATHOLOGY (2011)
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
Frank A. Sinicrope et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
Microsatellite instability in colorectal cancer-the stable evidence
Eduardo Vilar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M. Koopman et al.
BRITISH JOURNAL OF CANCER (2009)
Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer.
Sanford D. Markowitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer
Natasha Watson et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Effector memory T cells, early metastasis, and survival in colorectal cancer
F Pagès et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis
O Buhard et al.
DISEASE MARKERS (2004)
Development of a fluorescent multiplex assay for detection of MSI-high tumors
JW Bacher et al.
DISEASE MARKERS (2004)
Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways:: β2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors
CM Cabrera et al.
TISSUE ANTIGENS (2003)
Microsatellite instability and the clinicopathological features of sporadic colorectal cancer
R Ward et al.
GUT (2001)
Replication slippage involves DNA polymerase pausing and dissociation
E Viguera et al.
EMBO JOURNAL (2001)
Share Paper
